DETAILS
Description:
It is an inhibitor of type 2 sodium glucose cotransporter 2 (sglt-2). Sglt-2 inhibitor is a new hypoglycemic drug. It mainly reduces the reabsorption of glucose by kidney and increases the excretion of glucose in urine by inhibiting sglt-2 expressed in urine, so as to reduce the plasma glucose level. Its hypoglycemic effect does not depend on β Cell function
Empagliflozin, sold under the trade name Jardiance among others, is a medication used together with diet and exercise
to treat type 2 diabetes. It is less preferred than metformin and sulfonylureas. It may be used together with other
medications such as metformin It is not recommended for type 1 diabetes. It is taken by mouth.
Common side effects include urinary tract infections, fungal infections of the groin, and joint pains. Rarer but more
serious side effects include a skin infection of the groin called Fournier's gangrene and a form of diabetic ketoacidosis
with normal blood sugar levels. Use in pregnancy and breastfeeding is not recommended. Use is not recommended
in those with significant kidney disease, though it may help slow the progression of mild kidney problems. Empagliflozin
is an inhibitor of the sodium glucose co-transporter-2 (SGLT-2), and works by increasing sugar lost in the urine.
